Savara (SVRA) Tax Provisions (2017 - 2018)
Savara (SVRA) posted quarterly Tax Provisions of $2.5 million for Q4 2018, up 188.97% year-over-year from $865147.8 in Q4 2017, and up 2372.73% quarter-over-quarter from -$110000.0 in Q3 2018.
Savara (SVRA) Tax Provisions (2017 - 2018) Analysis & Trends
Savara (SVRA) has reported Tax Provisions for 2 consecutive years, with $2.5 million the latest figure, recorded in Q4 2018.
- In Q4 2018, Tax Provisions rose 188.97% year-over-year to $2.5 million; the TTM figure through Dec 2018 stood at -$2.4 million (up 32.8% YoY), while the FY2019 annual figure was -$16.4 million, down 13338.71% from the prior year.
- Tax Provisions grew to $2.5 million in Q4 2018 per SVRA's latest filing, from -$110000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $2.5 million in Q4 2018 and bottomed at -$4.6 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.50 Mn |
| Sep 30, 2018 | -110,000.00 |
| Jun 30, 2018 | -277,000.00 |
| Mar 31, 2018 | -4.56 Mn |
| Dec 31, 2017 | -2.81 Mn |
| Sep 30, 2017 | -117,000.00 |
| Jun 30, 2017 | -470,000.00 |
| Mar 31, 2017 | -237,000.00 |